Skip to main content
Interview with the Innovators
For this Interview with the Innovators series, several interviews were conducted with executives and scientists from Genmab, an international biotech company with 24 years of experience in developing cutting- edge antibodies and antibody technology. Read More ›

Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study. Read More ›

New Developments on Prognostic Markers for Patients With Early Breast Cancer
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials. Read More ›

Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study. Read More ›

Sanjay Juneja, MD, on the Approval of ORSERDU™
Dr Sanjay Juneja, medical oncologist and hematologist, and Chief of Oncology at Baton Rouge General Hospital–Mary Bird Perkins Cancer Center in Baton Rouge, LA, also known as “The Onc Doc,” is a well-known healthcare influencer. In the video above, Dr Juneja provides his perspectives on key efficacy and safety data from the EMERALD trial, the importance of testing for ESR1 mutations, and what the approval of ORSERDU (elacestrant) means for patients. Read More ›

Sagar D. Sardesai, MBBS, on the Approval of ORSERDU™
Dr. Sardesai, medical oncologist at The Ohio State University in Columbus, OH, discusses key considerations relating to the approval of ORSERDU (elacestrant), including appropriate patient selection, the clinical relevance of ESR1 mutations, and key takeaways from the EMERALD trial. Read More ›

Chaitali Nangia, MD, on the Approval of ORSERDU™
Dr. Nangia, medical oncologist at Hoag Medical Group in Irvine, CA, discusses key efficacy and safety data from the EMERALD trial, the importance of liquid biopsy testing, and changes in practice brought upon by the approval of ORSERDU (elacestrant). Read More ›

Yuan Yuan, MD, PhD, on the Approval of ORSERDU™
Dr Yuan, medical oncologist in Southern California, discusses key data from the EMERALD trial, the clinical relevance of ESR1 mutations, and changes in practice brought on by the approval of ORSERDU (elacestrant). Read More ›

Relapsed or Refractory FL: Best Practices for Active Surveillance & Reinforcement of Management Plans
Dr Tycel Phillips discusses the rationale of an “active surveillance” paradigm following initial diagnosis of follicular lymphoma (FL), as well as how to best select patients in whom this approach could be optimally applied, especially considering FL is currently still an incurable disease. Read More ›

Predicting High-Risk Disease Using Progression of Disease in 24 Months (POD24) and the Key Role of Repeat Biopsy to Exclude the Diagnosis of Transformation to a High-Grade Lymphoma in Patients with Relapsed Follicular Lymphoma
Dr Andrew Zelenetz explains the basis for the currently nearly universal use of the end point of “progression of disease in 24 months” (POD24) as a metric in patients with relapsed follicular lymphoma (FL) to identify a high-risk subpopulation. He also discusses how POD24 impacts the choice of therapy and assessing the impact of the next line of therapy. Dr Tycel Phillips emphasized the importance of repeat biopsy in patients with relapsed or refractory FL, to exclude the presence of histologic transformation of FL into a high-grade diffuse large B-cell lymphoma, which necessitates expeditious detection, staging, and aggressive therapy. Read More ›

Page 1 of 5